Overview

* iRhythm Q3 2025 revenue grows 30.7% yr/yr, beating analyst expectations, per LSEG data

* Gross margin improved to 71.1%, up 230 basis points from Q3 2024

* Adjusted net loss for Q3 2025 reduced significantly from prior year

Outlook

* iRhythm projects full-year 2025 revenue between $735 mln and $740 mln

* Adjusted EBITDA margin for 2025 expected to be 8.25% to 8.75%

* Company anticipates being free cash flow positive for 2025

Result Drivers

* ZIO SERVICES DEMAND - Revenue growth driven by increased demand for Zio services in core accounts and new channel partnerships

* GROSS MARGIN IMPROVEMENT - Gross margin improvement attributed to volume leverage and operational efficiencies

* INTERNATIONAL EXPANSION - Contribution from international markets supported revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $192.90 $184.74

Revenue mln mln (15

Analysts

)

Q3 -$2 mln

Adjusted

Net

Income

Q3 Net -$5.20

Income mln

Q3 Gross 71.10%

Margin

Q3 Gross $137.10

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for iRhythm Technologies Inc ( IRTC ) is $193.00, about 4% above its October 29 closing price of $185.29

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)